Source 1primary paper2019Nature Communications
Toolkit/upconversion nanoparticle
upconversion nanoparticle
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
An upconversion nanoparticle is used as a light-transducing component in an immunodevice that converts near-infrared input into activation of a UV light-activatable immunostimulatory agent. In the reported 2019 Nature Communications system, this enabled remote and spatially selective control of antitumor immunity in vitro and in vivo.
Usefulness & Problems
Why this is useful
This delivery harness is useful because it shifts a UV-responsive immunostimulatory system into the near-infrared optical window, allowing remote light control in a context where NIR illumination is used instead of direct UV exposure. The reported device supported localized immune regulation within tumors while avoiding disturbance of immunity elsewhere.
Source:
Here we report an activatable engineered immunodevice that enables remote control over the antitumor immunity in vitro and in vivo with near-infrared (NIR) light.
Problem solved
The tool addresses the problem that a UV light-activatable immunostimulatory agent is not directly matched to near-infrared illumination for remote control. By acting as a transducer that shifts device light sensitivity to the NIR window, the upconversion nanoparticle enables spatially selective triggering of antitumor immunity.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Techniques
Computational DesignTarget processes
No target processes tagged yet.
Input: Light
Implementation Constraints
In the reported implementation, the upconversion nanoparticle is combined with a rationally designed UV light-activatable immunostimulatory agent to form the immunodevice. Practical details such as nanoparticle material, construct stoichiometry, formulation, and delivery route are not provided in the supplied evidence.
The supplied evidence describes the nanoparticle only within a single immunodevice study and does not provide broader comparative benchmarking or independent replication. The evidence also does not specify nanoparticle composition, emission wavelengths, dosing, or generalizability beyond the reported antitumor immune application.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The activatable engineered immunodevice enables remote control of antitumor immunity with near-infrared light in vitro and in vivo.
Here we report an activatable engineered immunodevice that enables remote control over the antitumor immunity in vitro and in vivo with near-infrared (NIR) light.
The activatable engineered immunodevice enables remote control of antitumor immunity with near-infrared light in vitro and in vivo.
Here we report an activatable engineered immunodevice that enables remote control over the antitumor immunity in vitro and in vivo with near-infrared (NIR) light.
The activatable engineered immunodevice enables remote control of antitumor immunity with near-infrared light in vitro and in vivo.
Here we report an activatable engineered immunodevice that enables remote control over the antitumor immunity in vitro and in vivo with near-infrared (NIR) light.
The activatable engineered immunodevice enables remote control of antitumor immunity with near-infrared light in vitro and in vivo.
Here we report an activatable engineered immunodevice that enables remote control over the antitumor immunity in vitro and in vivo with near-infrared (NIR) light.
The activatable engineered immunodevice enables remote control of antitumor immunity with near-infrared light in vitro and in vivo.
Here we report an activatable engineered immunodevice that enables remote control over the antitumor immunity in vitro and in vivo with near-infrared (NIR) light.
The activatable engineered immunodevice enables remote control of antitumor immunity with near-infrared light in vitro and in vivo.
Here we report an activatable engineered immunodevice that enables remote control over the antitumor immunity in vitro and in vivo with near-infrared (NIR) light.
The activatable engineered immunodevice enables remote control of antitumor immunity with near-infrared light in vitro and in vivo.
Here we report an activatable engineered immunodevice that enables remote control over the antitumor immunity in vitro and in vivo with near-infrared (NIR) light.
The immunodevice is composed of a UV light-activatable immunostimulatory agent and an upconversion nanoparticle that shifts device light sensitivity to the NIR window.
The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window.
The immunodevice is composed of a UV light-activatable immunostimulatory agent and an upconversion nanoparticle that shifts device light sensitivity to the NIR window.
The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window.
The immunodevice is composed of a UV light-activatable immunostimulatory agent and an upconversion nanoparticle that shifts device light sensitivity to the NIR window.
The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window.
The immunodevice is composed of a UV light-activatable immunostimulatory agent and an upconversion nanoparticle that shifts device light sensitivity to the NIR window.
The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window.
The immunodevice is composed of a UV light-activatable immunostimulatory agent and an upconversion nanoparticle that shifts device light sensitivity to the NIR window.
The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window.
The immunodevice is composed of a UV light-activatable immunostimulatory agent and an upconversion nanoparticle that shifts device light sensitivity to the NIR window.
The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window.
The immunodevice is composed of a UV light-activatable immunostimulatory agent and an upconversion nanoparticle that shifts device light sensitivity to the NIR window.
The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window.
Controlled immune regulation by the immunodevice allows effective immune response within tumor without disturbing immunity elsewhere, maintaining antitumor efficacy while mitigating systemic toxicity.
The controlled immune regulation allows the generation of effective immune response within tumor without disturbing immunity elsewhere in the body, thereby maintaining the antitumor efficacy while mitigating systemic toxicity.
Controlled immune regulation by the immunodevice allows effective immune response within tumor without disturbing immunity elsewhere, maintaining antitumor efficacy while mitigating systemic toxicity.
The controlled immune regulation allows the generation of effective immune response within tumor without disturbing immunity elsewhere in the body, thereby maintaining the antitumor efficacy while mitigating systemic toxicity.
Controlled immune regulation by the immunodevice allows effective immune response within tumor without disturbing immunity elsewhere, maintaining antitumor efficacy while mitigating systemic toxicity.
The controlled immune regulation allows the generation of effective immune response within tumor without disturbing immunity elsewhere in the body, thereby maintaining the antitumor efficacy while mitigating systemic toxicity.
Controlled immune regulation by the immunodevice allows effective immune response within tumor without disturbing immunity elsewhere, maintaining antitumor efficacy while mitigating systemic toxicity.
The controlled immune regulation allows the generation of effective immune response within tumor without disturbing immunity elsewhere in the body, thereby maintaining the antitumor efficacy while mitigating systemic toxicity.
Controlled immune regulation by the immunodevice allows effective immune response within tumor without disturbing immunity elsewhere, maintaining antitumor efficacy while mitigating systemic toxicity.
The controlled immune regulation allows the generation of effective immune response within tumor without disturbing immunity elsewhere in the body, thereby maintaining the antitumor efficacy while mitigating systemic toxicity.
Controlled immune regulation by the immunodevice allows effective immune response within tumor without disturbing immunity elsewhere, maintaining antitumor efficacy while mitigating systemic toxicity.
The controlled immune regulation allows the generation of effective immune response within tumor without disturbing immunity elsewhere in the body, thereby maintaining the antitumor efficacy while mitigating systemic toxicity.
Controlled immune regulation by the immunodevice allows effective immune response within tumor without disturbing immunity elsewhere, maintaining antitumor efficacy while mitigating systemic toxicity.
The controlled immune regulation allows the generation of effective immune response within tumor without disturbing immunity elsewhere in the body, thereby maintaining the antitumor efficacy while mitigating systemic toxicity.
Approval Evidence
1 source1 linked approval claimfirst-pass slug upconversion-nanoparticle
The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window.
Source:
compositionsupports
The immunodevice is composed of a UV light-activatable immunostimulatory agent and an upconversion nanoparticle that shifts device light sensitivity to the NIR window.
The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window.
Source:
Comparisons
Source-backed strengths
The reported system achieved remote control of antitumor immunity with NIR light both in vitro and in vivo. Controlled immune regulation was reported to maintain antitumor efficacy while mitigating systemic toxicity by confining effective immune responses within the tumor.
Ranked Citations
- 1.